Lv Ying, Bian Huiying, Jing Yanjia, Zhou Jing
Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Department of Dermatology, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
J Transl Med. 2025 Jul 24;23(1):817. doi: 10.1186/s12967-025-06723-9.
The IL-17A inhibitors target aberrant immune responses in psoriasis but also impacts the host's defense against infections. The effects of this treatment on skin microorganisms and microbiome-encoded metabolic pathways remain unclear.
This was an exploratory clinical study designed to investigate whether Psoriasis is associated with skin microbiota, as well as a longitudinal cohort study aimed at revealing the effects of IL-17A inhibitor treatment on skin microbiota in Psoriasis.
In this study, we recruited 26 patients with moderate to severe psoriasis and 15 healthy controls. We collected skin microbiome samples from both greasy and dry skin regions. All samples were analyzed using 16S rDNA gene sequencing to determine the microbial profiles.
Compared with healthy controls, the composition and function of skin microbiome in psoriasis patients are heterogeneous. Treatment with IL-17A inhibitors significantly increases the alpha diversity of the skin microbiota in psoriasis patients, indicating potential restoration of microbial community richness and evenness. However, this treatment does not entirely alter the taxonomic composition of the skin microbiota; rather, it shifts the relative abundance of specific microbial species, indicating that certain core microbial features remain relatively stable. Moreover, IL-17A inhibitors help adjust the functional profile of the skin microbiome in psoriasis patients, bringing it closer to that of healthy individuals.
Psoriasis patients exhibit significant heterogeneity in both the composition and functionality of their skin microbiota. Although IL-17A inhibitor treatment fails to fundamentally alter its taxonomic composition, this therapy effectively enhances microbial community stability by increasing alpha diversity and modulating the relative abundance of various taxa. Additionally, it adjusts the functional profile of the skin microbiota towards a healthier state, thereby contributing to the restoration of microecological balance.
白细胞介素-17A(IL-17A)抑制剂可靶向治疗银屑病中异常的免疫反应,但也会影响宿主对感染的防御能力。这种治疗方法对皮肤微生物群和微生物群编码的代谢途径的影响尚不清楚。
这是一项探索性临床研究,旨在调查银屑病是否与皮肤微生物群相关,也是一项纵向队列研究,旨在揭示IL-17A抑制剂治疗对银屑病患者皮肤微生物群的影响。
在本研究中,我们招募了26例中度至重度银屑病患者和15名健康对照者。我们从油性和干性皮肤区域采集了皮肤微生物群样本。所有样本均使用16S核糖体DNA(rDNA)基因测序进行分析,以确定微生物谱。
与健康对照者相比,银屑病患者皮肤微生物群的组成和功能具有异质性。用IL-17A抑制剂治疗可显著增加银屑病患者皮肤微生物群的α多样性,表明微生物群落丰富度和均匀度可能得到恢复。然而,这种治疗并没有完全改变皮肤微生物群的分类组成;相反,它改变了特定微生物物种的相对丰度,表明某些核心微生物特征保持相对稳定。此外,IL-17A抑制剂有助于调整银屑病患者皮肤微生物群的功能谱,使其更接近健康个体。
银屑病患者的皮肤微生物群在组成和功能上均表现出显著的异质性。虽然IL-17A抑制剂治疗未能从根本上改变其分类组成,但该疗法通过增加α多样性和调节各种分类群的相对丰度,有效地增强了微生物群落的稳定性。此外,它将皮肤微生物群的功能谱调整到更健康的状态,从而有助于恢复微生态平衡。